COPD Drug Market Opportunity & Clinical Pipeline Analysis

Description: Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death.

The prevalence and incidence of this disease is increasing worldwide. Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. In spite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease.

There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler. There has been significant expansion in the COPD drug market in the recent years and it is expected that this market would record high growth over the next decade. The major driving force in the future would be a greater demand for new drugs with higher and better efficiency.

This market has been recognized to be one with many opportunities which are yet to be tapped. Hence, the leading pharma companies are increasing their focus on this segment by introducing new combination drugs and novel agents. The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018.

COPD Drug Market Opportunity & Clinical Pipeline Analysis

Report Highlight:

* COPD Drug Market Overview
* COPD Patient Base: Global, US & Europe
* FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
* COPD Drug Clinical Pipeline by Phase & Country
* COPD Drug in Development Phase: 174
* Majority of COPD Drugs in Preclinical Phase: 72
* Marketed COPD Drugs: 36
* Discontinued & Suspended COPD Drug Profiles

Contents:

1. Global Chronic Obstructive Pulmonary Disease Market Overview
   1.1 Market Overview
   1.2 Clinical Trial Analysis

2. EMA Guideline on Clinical Investigation of COPD Drugs
   2.1 Introduction
   2.2 Legal Basis & Relevant Guidelines
   2.3 Patient Characteristics & Selection Of Patients
   2.4 Methods to Assess Efficacy
   2.5 Strategy & Design Of Clinical Trials
   2.6 Safety

3. FDA Guideline on Clinical Investigation of COPD Drugs
   3.1 Disease Target and Indication
   3.2 Types of Drugs for COPD
3.3 Drug Development Population
3.4 Dose Selection
3.5 Efficacy Assessment
3.6 Recommended Primary and Secondary Efficacy Endpoints
3.7 Study Duration
3.8 Number of Studies
3.9 Considerations Regarding Demonstration of Efficacy
3.10 Considerations Regarding Demonstration of Safety
3.11 Specific Efficacy Study Considerations

4. Chronic Obstructive Pulmonary Disease Drug Clinical Trial by Phase & Country
4.1 Phase Unknown
4.2 Research
4.3 Preclinical
4.4 Clinical
4.5 Phase I
4.6 Phase I/II
4.7 Phase II
4.8 Phase III
4.9 Preregistration
4.10 Registered

5. Marketed Drugs for Chronic Obstructive Pulmonary Disease by Country

6. No Development, Discontinued & Suspended Drug Clinical Trial by Phase & Country
6.1 No Development Reported
6.2 Discontinued
6.3 Market Withdrawal
6.4 Suspended

7. Competitive Landscape
7.1 Almirall
7.2 AstraZeneca
7.3 Boehringer Ingelheim
7.4 Bayer
7.5 Chiesi Farmaceutici
7.6 Forest Laboratories
7.7 Lallemand Pharma
7.8 Merck & Co
7.9 Novartis
7.10 Sunovion Pharmaceuticals

List Of Figures:

Figure 1-1: Global - People Suffering With COPD (Million), 2013-2018
Figure 1-2: US - People Suffering With COPD (Million), 2013-2018
Figure 1-3: US - People Suffering With COPD by Age Group (%)
Figure 1-4: Europe - People Suffering With COPD (Million), 2013-2018
Figure 1-5: Europe – Death from COPD (’000), 2005 & 2030
Figure 1-6: Global COPD Drug Market (US$ Billion), 2012-2018
Figure 1-7: Number of COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-8: COPD Drugs in Clinical Trial by Phase (%), 2014
Figure 1-9: Number of Discontinued COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-10: Discontinued COPD Drugs in Clinical Trial by Phase (%), 2014
Figure 1-11: Number of Suspended COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-12: Suspended COPD Drugs in Clinical Trial by Phase (%), 2014
Figure 1-13: Number of No Development in COPD Drugs in Clinical Trial by Phase, 2014
Figure 1-14: No Development in COPD Drugs in Clinical Trial by Phase (%), 2014

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: COPD Drug Market Opportunity & Clinical Pipeline Analysis
Web Address: http://www.researchandmarkets.com/reports/2814265/
Office Code: SCH336FA

Product Formats
Please select the product formats and quantity you require:

| Quantity           | Hard Copy: USD 2600 + USD 58 Shipping/Handling
|--------------------|-----------------------------------------------
|                    | CD-ROM: USD 2400 + USD 58 Shipping/Handling   
|                    | Electronic (PDF) - Single User: USD 2200      
|                    | Electronic (PDF) - Enterprisewide: USD 3600  

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World